State System Development Initiative (SSDI) Grant Program; Single-Case Deviation From Competition Requirements, 58546-58547 [2013-23074]
Download as PDF
<![CDATA[
58546
Federal Register / Vol. 78, No. 185 / Tuesday, September 24, 2013 / Notices
a fax request to 301–847–8149 to receive
a hard copy. Please use the document
number 1831 to identify the guidance
you are requesting.
IV. Paperwork Reduction Act of 1995
This draft guidance refers to proposed
collections of information described in
FDA’s July 10, 2012, proposed rule on
the UDI system (77 FR 40736), which
this draft guidance is intended to
interpret. The proposed collections of
information in the proposed rule are
subject to review by the Office of
Management and Budget (OMB) under
the Paperwork Reduction Act of 1995
(the PRA) (44 U.S.C. 3501–3520). As
required by the PRA, FDA has
published an analysis of the information
collection provisions of the proposed
rule (77 FR 40736 at 40762) and has
submitted them for OMB approval
(OMB control number 0910–0720).
V. Comments
Interested persons may submit either
electronic comments regarding this
document to https://www.regulations.gov
or written comments to the Division of
Dockets Management (see ADDRESSES). It
is only necessary to send one set of
comments. Identify comments with the
docket number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday, and
will be posted to the docket at https://
www.regulations.gov.
Dated: September 18, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013–23058 Filed 9–20–13; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH & HUMAN
SERVICES
Health Resources and Services
Administration
State System Development Initiative
(SSDI) Grant Program; Single-Case
Deviation From Competition
Requirements
Health Resources and Services
Administration (HRSA), Department of
Health and Human Services (HHS).
mstockstill on DSK4VPTVN1PROD with NOTICES
AGENCY:
Notice of Single-Case Deviation
from Competition Requirements for the
Maternal and Child Health (MCH)
Bureau’s States System Development
Initiative (SSDI) Grant.
ACTION:
HRSA will be issuing a noncompetitive program expansion
supplement for one State SSDI Grant.
Approximately $82,332 in supplemental
funding will be made available in the
form of a grant to the Department of
Health Care Services, Sacramento,
California, Grant Number H18MC24474,
during the budget period of December 1,
2012, through November 30, 2013.
The SSDI Grant program, CFDA No.
93.110, is authorized by Title V, Social
Security Act, Section 501(a)(2); as
amended (42 U.S.C. 701(a)(2)).
The SSDI Grant program was
developed to complement the Title V
MCH Services Block Grant program by
assisting state MCH and Children with
Special Health Care Needs (CSHCN)
programs in the building of state data
capacity and infrastructure that support
comprehensive, community-based
systems of care for all children and their
families. SSDI grants to states are
intended to not only advance and
strengthen data capacity by directing
grant resources towards Title V MCH
Block Grant program’s Health Systems
Capacity Indicator (HSCI) #09A (i.e., the
ability of states to assure that the MCH
programs and Title V agency have
access to policy and program relevant
information and data), but also to move
states forward in developing improved
capacity for reporting standardized and
quality data that is timely.
SUPPLEMENTARY INFORMATION:
Intended Recipient of the Award:
Department of Health Care Services,
Sacramento, California.
Amount of the Non-Competitive
Award: $82,332.
CFDA Number: 93.110.
Current Project Period: 05/01/2012–
11/30/2014.
Period of Supplemental Funding: 12/
01/2012–11/30/2013.
SUMMARY:
health of all mothers and children, a key
objective of the Title V MCH Block
Grant program is to reduce maternal
mortality. Due to small numbers for
many states, maternal mortality cannot
be universally tracked whereas severe,
life-threatening maternal morbidity is at
least 100 times as common and may be
tracked annually for all states. Although
a severe maternal morbidity index has
been developed using administrative
hospital discharge data, a validation in
comparison to medical records is
needed to determine whether its
accuracy is sufficient for use as a
national performance measure reported
at the state level.
The California Title V MCH program
has been a leader in assessing maternal
mortality and conducting maternal
mortality reviews. In particular, the
California Maternal Quality Care
Collaborative (CMQCC) is the oldest and
largest maternity care collaborative in
the country with a longstanding track
record of analyzing maternal health data
and developing metrics to improve
clinical practice and prevent maternal
death and injury. The promising work
that the California Title V program is
doing stands to benefit not only the state
but all state MCH programs in
promoting a better understanding of the
causes of maternal mortality/morbidity
and in offering potential solutions.
Based on their prior work, established
data networks, and sheer size of their
birth cohort, the State of California is
uniquely qualified to evaluate and make
recommendations for a state-level severe
maternal morbidity measure.
FOR FURTHER INFORMATION CONTACT:
Scott Snyder, MPH, Division of State
and Community Health, Maternal and
Child Health Bureau, Health Resources
and Services Administration, 5600
Fishers Lane, Room 18–31, Rockville,
Maryland 20857; ssnyder@hrsa.gov.
Authority: Title V, Social Security Act,
Section 501(a)(2); as amended (42 U.S.C.
701).
Justification: Consistent with its
legislative purpose to improve the
Grantee/organization name
Grant No.
State
Department of Health Care Services ......................................................................
H18MC24474
CA ..........
VerDate Mar<15>2010
19:49 Sep 23, 2013
Jkt 229001
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
E:\FR\FM\24SEN1.SGM
24SEN1
FY 2013
authorized
funding
level
$100,000
FY 2013
estimated
supplemental
funding
$82,332
Federal Register / Vol. 78, No. 185 / Tuesday, September 24, 2013 / Notices
Place: National Institutes of Health, Two
Democracy Plaza, Suite 920, 6707 Democracy
Boulevard, Bethesda, MD 20892, (Virtual
Meeting).
Contact Person: Ruixia Zhou, Ph.D.,
Scientific Review Officer, 6707 Democracy
Boulevard, Suite 957, Bethesda, MD 20892,
301–496–4773, zhour@mail.nih.gov.
Dated: September 17, 2013.
Mary K. Wakefield,
Administrator.
[FR Doc. 2013–23074 Filed 9–23–13; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: September 18, 2013.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
National Institutes of Health
Center for Scientific Review; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the Medical Imaging
Study Section, October 07, 2013, 08:00
a.m. to October 08, 2013, 05:00 p.m.,
National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD, 20892
which was published in the Federal
Register on September 10, 2013, FR 78
55268–55270.
The meeting will be held October 7,
2013, 9:30 a.m. to 5:30 p.m. The meeting
location remains the same. The meeting
is closed to the public.
Dated: September 18, 2013.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2013–23081 Filed 9–23–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
mstockstill on DSK4VPTVN1PROD with NOTICES
National Institute of Biomedical
Imaging and Bioengineering; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Biomedical Imaging and Bioengineering
Special Emphasis Panel; 2014–01 Reducing
Health Disparity SBIR Review.
Date: November 8, 2013.
Time: 10:00 a.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
VerDate Mar<15>2010
19:49 Sep 23, 2013
Jkt 229001
[FR Doc. 2013–23083 Filed 9–23–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Neurobiology, genetics, stress and mood/
anxiety disorders.
Date: October 10, 2013.
Time: 5:30 p.m. to 6:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites Washington, DC
Convention Center, 900 10th Street NW.,
Washington, DC 20001.
Contact Person: Jay Joshi, Ph.D., Scientific
Review Officer, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 5196, MSC 7846, Bethesda, MD
20892, (301) 408–9135, joshij@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Non-HIV Microbial Vaccine
Development.
Date: October 18, 2013.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Scott Jakes, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4198,
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
58547
MSC 7812, Bethesda, MD 20892, 301–495–
1506, jakesse@mail.nih.gov.
Name of Committee: Healthcare Delivery
and Methodologies Integrated Review Group;
Biostatistical Methods and Research Design
Study Section.
Date: October 18, 2013.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Holiday Inn Inner Harbor, 301 W.
Lombard Street, Baltimore, MD 21201.
Contact Person: Tomas Drgon, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3152,
MSC 7770, Bethesda, MD 20892, 301–435–
1017, tdrgon@csr.nih.gov.
Name of Committee: Oncology 2—
Translational Clinical Integrated Review
Group; Cancer Biomarkers Study Section.
Date: October 18, 2013.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Houston JW Marriott, 5150
Westheimer Road, Houston, TX 77056.
Contact Person: Lawrence Ka-Yun Ng,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6152,
MSC 7804, Bethesda, MD 20892, 301–357–
9318, ngkl@csr.nih.gov.
Name of Committee: Infectious Diseases
and Microbiology Integrated Review Group;
Host Interactions with Bacterial Pathogens
Study Section.
Date: October 18, 2013.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Fouad A El-Zaatari, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3186,
MSC 7808, Bethesda, MD 20892, (301) 435–
1149, elzaataf@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Risk, Prevention and Health
Behavior.
Date: October 18, 2013.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
Contact Person: Claire E Gutkin, Ph.D.,
MPH, Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3106,
MSC 7808, Bethesda, MD 20892, 301–594–
3139, gutkincl@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Molecular
Neuroscience of Channels and Receptors.
Date: October 18, 2013.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
E:\FR\FM\24SEN1.SGM
24SEN1
]]>Agencies
[Federal Register Volume 78, Number 185 (Tuesday, September 24, 2013)]
[Notices]
[Pages 58546-58547]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-23074]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH & HUMAN SERVICES
Health Resources and Services Administration
State System Development Initiative (SSDI) Grant Program; Single-
Case Deviation From Competition Requirements
AGENCY: Health Resources and Services Administration (HRSA), Department
of Health and Human Services (HHS).
ACTION: Notice of Single-Case Deviation from Competition Requirements
for the Maternal and Child Health (MCH) Bureau's States System
Development Initiative (SSDI) Grant.
-----------------------------------------------------------------------
SUMMARY: HRSA will be issuing a non-competitive program expansion
supplement for one State SSDI Grant. Approximately $82,332 in
supplemental funding will be made available in the form of a grant to
the Department of Health Care Services, Sacramento, California, Grant
Number H18MC24474, during the budget period of December 1, 2012,
through November 30, 2013.
The SSDI Grant program, CFDA No. 93.110, is authorized by Title V,
Social Security Act, Section 501(a)(2); as amended (42 U.S.C.
701(a)(2)).
The SSDI Grant program was developed to complement the Title V MCH
Services Block Grant program by assisting state MCH and Children with
Special Health Care Needs (CSHCN) programs in the building of state
data capacity and infrastructure that support comprehensive, community-
based systems of care for all children and their families. SSDI grants
to states are intended to not only advance and strengthen data capacity
by directing grant resources towards Title V MCH Block Grant program's
Health Systems Capacity Indicator (HSCI) 09A (i.e., the
ability of states to assure that the MCH programs and Title V agency
have access to policy and program relevant information and data), but
also to move states forward in developing improved capacity for
reporting standardized and quality data that is timely.
SUPPLEMENTARY INFORMATION:
Intended Recipient of the Award: Department of Health Care
Services, Sacramento, California.
Amount of the Non-Competitive Award: $82,332.
CFDA Number: 93.110.
Current Project Period: 05/01/2012-11/30/2014.
Period of Supplemental Funding: 12/01/2012-11/30/2013.
Authority: Title V, Social Security Act, Section 501(a)(2); as
amended (42 U.S.C. 701).
Justification: Consistent with its legislative purpose to improve
the health of all mothers and children, a key objective of the Title V
MCH Block Grant program is to reduce maternal mortality. Due to small
numbers for many states, maternal mortality cannot be universally
tracked whereas severe, life-threatening maternal morbidity is at least
100 times as common and may be tracked annually for all states.
Although a severe maternal morbidity index has been developed using
administrative hospital discharge data, a validation in comparison to
medical records is needed to determine whether its accuracy is
sufficient for use as a national performance measure reported at the
state level.
The California Title V MCH program has been a leader in assessing
maternal mortality and conducting maternal mortality reviews. In
particular, the California Maternal Quality Care Collaborative (CMQCC)
is the oldest and largest maternity care collaborative in the country
with a longstanding track record of analyzing maternal health data and
developing metrics to improve clinical practice and prevent maternal
death and injury. The promising work that the California Title V
program is doing stands to benefit not only the state but all state MCH
programs in promoting a better understanding of the causes of maternal
mortality/morbidity and in offering potential solutions. Based on their
prior work, established data networks, and sheer size of their birth
cohort, the State of California is uniquely qualified to evaluate and
make recommendations for a state-level severe maternal morbidity
measure.
FOR FURTHER INFORMATION CONTACT: Scott Snyder, MPH, Division of State
and Community Health, Maternal and Child Health Bureau, Health
Resources and Services Administration, 5600 Fishers Lane, Room 18-31,
Rockville, Maryland 20857; ssnyder@hrsa.gov.
----------------------------------------------------------------------------------------------------------------
FY 2013
FY 2013 estimated
Grantee/organization name Grant No. State authorized supplemental
funding level funding
----------------------------------------------------------------------------------------------------------------
Department of Health Care Services..... H18MC24474 CA..................... $100,000 $82,332
----------------------------------------------------------------------------------------------------------------
[[Page 58547]]
Dated: September 17, 2013.
Mary K. Wakefield,
Administrator.
[FR Doc. 2013-23074 Filed 9-23-13; 8:45 am]
BILLING CODE 4165-15-P
